COMPUTED DESCRIPTORS
| Molecular Weight | 1241.3 g/mol |
|---|---|
| Hydrogen Bond Donor Count | 10 |
| Hydrogen Bond Acceptor Count | 30 |
| Rotatable Bond Count | 19 |
| Exact Mass | 1240.51623892 g/mol |
| Monoisotopic Mass | 1240.51623892 g/mol |
| Topological Polar Surface Area | 443 Ų |
| Heavy Atom Count | 90 |
| Formal Charge | 0 |
| Complexity | 728 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 5 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Lanraplenib Succinate is the succinate salt form of lanraplenib, an orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration, lanraplenib binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.